Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19876941 | 0.94 | KCNH2 (0.50) | DRD2DRD4DRD3 | |
| SCHEMBL12844627 | 0.90 | DRD2 (0.51) | DRD2DRD4DRD3FFAR1KDM4E | |
| SCHEMBL5543626 | 0.83 | DRD2 (0.49) | DRD2DRD4DRD3FFAR1ALDH1A1 | |
| SCHEMBL12432902 | 0.82 | DRD2 (0.54) | DRD2DRD4DRD3FFAR1ALDH1A1 | |
| SCHEMBL5536850 | 0.82 | DRD2 (0.48) | DRD2DRD4DRD3FFAR1ALDH1A1 | |
| SCHEMBL27610597 | 0.80 | NPC1 (0.45) | NPC1MAPTRAB9A | |
| SCHEMBL5106193 | 0.79 | DRD2 (0.51) | DRD2DRD4DRD3FFAR1ALDH1A1 | |
| SCHEMBL2225947 | 0.79 | DRD2 (0.51) | DRD2DRD4DRD3FFAR1ALDH1A1 | |
| SCHEMBL5541970 | 0.79 | DRD2 (0.55) | DRD2DRD4DRD3FFAR1KDM4E | |
| SCHEMBL9282001 | 0.78 | CYP1A2 (0.43) | KDM4ENPC1ALDH1A1MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | DRD2 3243/4885DRD4 4199/4885DRD3 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.